Immune checkpoint blockade (ICB), which has revolutionized treatment paradigms across multiple cancer types, has demonstrated only modest efficacy in breast cancer, with anti-PD-1/PD-L1 and anti-CTLA4 monoclonal antibodies benefiting a small subset of patients with predominantly PD-L1-positive tumors7–10. This evidence concerns the gene CD274 and cancer.